Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6333897 | 0.90 | MEN1 (0.40) | MEN1KMT2ACYP1A2CYP2C19PTGS1 | |
| SCHEMBL6335690 | 0.82 | TSHR (0.38) | MEN1KMT2ACYP1A2LMNATSHR | |
| SCHEMBL6335754 | 0.81 | CNR2 (0.32) | MEN1KMT2ACYP1A2CYP2C19PTGS1 | |
| SCHEMBL6335208 | 0.81 | MEN1 (0.40) | MEN1KMT2ACYP1A2CYP2C19PTGS1 | |
| SCHEMBL6342501 | 0.80 | TSHR (0.31) | TSHR | |
| SCHEMBL6335241 | 0.80 | MEN1 (0.35) | MEN1KMT2ACYP1A2CYP2C19TSHR | |
| SCHEMBL6336215 | 0.80 | ALDH1A1 (0.36) | CYP1A2LMNATDP1 | |
| SCHEMBL6335530 | 0.78 | MEN1 (0.31) | MEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL6828228 | 0.74 | CYP1A2 (0.43) | MEN1KMT2ACYP1A2CYP2C19PTGS1 | |
| SCHEMBL6823068 | 0.72 | LRRK2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1456201-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003053957-A1 | BENZHYDRYL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | MEN1 550/4885KMT2A 2775/4885CYP1A2 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.